Last updated on September 2017

Tralokinumab monotherapy for moderate to severe atopic dermatitis.


Brief description of study

Tralokinumab monotherapy for moderate to severe atopic dermatitis.

Detailed Study Description

Tralokinumab monotherapy for moderate to severe atopic dermatitis.

Clinical Study Identifier: TX14953

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jalyssa Rodriguez

Psoriasis Treatment Center of Central New Jersey
East Windsor, NJ USA
  Connect »